{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T14:54:03Z","timestamp":1794581643090,"version":"4.9.1"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007219","name":"Natural Science Foundation of Shanghai","doi-asserted-by":"publisher","award":["19ZR140620"],"award-info":[{"award-number":["19ZR140620"]}],"id":[{"id":"10.13039\/100007219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81473150"],"award-info":[{"award-number":["81473150"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81690263"],"award-info":[{"award-number":["81690263"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003702"],"award-info":[{"award-number":["82003702"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073780"],"award-info":[{"award-number":["82073780"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jconrel.2023.01.074","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T06:35:59Z","timestamp":1676529359000},"page":"604-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer's disease"],"prefix":"10.1016","volume":"355","author":[{"given":"Qian","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kang","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongyu","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuchang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinxu","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichang","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qizhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.01.074_bb0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41583-019-0240-3","article-title":"Amyloid-\u03b2-independent regulators of tau pathology in Alzheimer disease","volume":"21","author":"van der Kant","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0010","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","article-title":"Alzheimer's disease","volume":"397","author":"Scheltens","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0015","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.cell.2012.02.040","article-title":"Alzheimer mechanisms and therapeutic strategies","volume":"148","author":"Huang","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0020","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0025","doi-asserted-by":"crossref","first-page":"S611","DOI":"10.3233\/JAD-179935","article-title":"Role of amyloid-\u03b2 and tau proteins in Alzheimer\u2019s disease: confuting the amyloid Cascade","volume":"64","author":"Gulisano","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0030","doi-asserted-by":"crossref","first-page":"120861","DOI":"10.1016\/j.lfs.2022.120861","article-title":"Alzheimer\u2019s disease failed clinical trials","volume":"306","author":"Asher","year":"2022","journal-title":"Life Sci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0035","article-title":"Advancing combination therapy for Alzheimer's disease","volume":"6","author":"Salloway","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093272","article-title":"Combination drug therapy for the Management of Alzheimer\u2019s disease","volume":"21","author":"Kabir","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0045","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/bs.pmbts.2019.10.001","article-title":"Combination therapy for Alzheimer\u2019s disease and related dementias","volume":"168","author":"Bednar","year":"2019","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0050","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1080\/14656566.2018.1519022","article-title":"An evaluation of memantine ER + donepezil for the treatment of Alzheimer\u2019s disease","volume":"19","author":"Calhoun","year":"2018","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0055","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.trci.2018.03.009","article-title":"Alzheimer's disease drug development pipeline: 2018","volume":"4","author":"Cummings","year":"2018","journal-title":"Alzheimers Dement (N Y)"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0060","doi-asserted-by":"crossref","first-page":"11310","DOI":"10.1074\/jbc.M116.762658","article-title":"Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer\u2019s disease","volume":"292","author":"Mori","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0065","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.neuron.2008.11.007","article-title":"Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis","volume":"60","author":"Small","year":"2008","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nm.4443","article-title":"Amyloid-\u03b2 plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation","volume":"24","author":"He","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0075","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.neurobiolaging.2019.03.016","article-title":"Relevance of the interplay between amyloid and tau for cognitive impairment in early Alzheimer\u2019s disease","volume":"79","author":"Timmers","year":"2019","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0080","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2174\/156720506779025242","article-title":"Pathways by which Abeta facilitates tau pathology","volume":"3","author":"Blurton-Jones","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/nrneurol.2017.162","article-title":"Amyloid-\u03b2 and tau complexity - towards improved biomarkers and targeted therapies","volume":"14","author":"Polanco","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0090","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1042\/BST0380993","article-title":"Pathways linking Abeta and tau pathologies","volume":"38","author":"LaFerla","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0095","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2010.06.036","article-title":"Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models","volume":"142","author":"Ittner","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0100","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s12035-014-8994-0","article-title":"The binding receptors of A\u03b2: an alternative therapeutic target for Alzheimer\u2019s disease","volume":"53","author":"Xia","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0105","doi-asserted-by":"crossref","first-page":"975","DOI":"10.3233\/JAD-160612","article-title":"Amyloid-beta and phosphorylated tau accumulations cause abnormalities at synapses of Alzheimer\u2019s disease neurons","volume":"57","author":"Rajmohan","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0110","doi-asserted-by":"crossref","first-page":"20057","DOI":"10.1073\/pnas.0905529106","article-title":"Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer\u2019s disease mice","volume":"106","author":"Rhein","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0115","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nrn2967","article-title":"Amyloid-\u03b2 and tau--a toxic pas de deux in Alzheimer\u2019s disease","volume":"12","author":"Ittner","year":"2011","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0120","article-title":"Feasibility of \u03b2-sheet breaker peptide-H102 treatment for Alzheimer's disease based on \u03b2-amyloid hypothesis","volume":"9","author":"Lin","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0125","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jconrel.2014.07.050","article-title":"The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer\u2019s disease","volume":"192","author":"Zhang","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0130","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.nbd.2009.02.011","article-title":"NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model","volume":"34","author":"Shiryaev","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0135","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1385\/JMN\/31:02:165","article-title":"Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer\u2019s disease at early pathological stage","volume":"31","author":"Matsuoka","year":"2007","journal-title":"J. Mol. Neurosci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0140","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.jconrel.2020.01.039","article-title":"A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer\u2019s disease mice","volume":"320","author":"Guo","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0145","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1527-3458.2005.tb00053.x","article-title":"NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP)","volume":"11","author":"Gozes","year":"2005","journal-title":"CNS Drug Rev."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0150","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1007\/s11095-015-1744-9","article-title":"Intranasal H102 peptide-loaded liposomes for brain delivery to treat Alzheimer\u2019s disease","volume":"32","author":"Zheng","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0155","doi-asserted-by":"crossref","first-page":"9518","DOI":"10.1021\/nn405674m","article-title":"Nanoparticles for combination drug therapy","volume":"7","author":"Ma","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0160","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.4155\/tde.13.104","article-title":"Basics and recent advances in peptide and protein drug delivery","volume":"4","author":"Bruno","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0165","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jconrel.2018.04.034","article-title":"Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer\u2019s disease","volume":"279","author":"Wang","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0170","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1007\/s11095-013-1025-4","article-title":"Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides","volume":"30","author":"Li","year":"2013","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0175","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/acsnano.7b07625","article-title":"Tau-targeted multifunctional nanocomposite for combinational therapy of Alzheimer\u2019s disease","volume":"12","author":"Chen","year":"2018","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0180","first-page":"300","article-title":"Modulating autophagic flux via ROS-responsive targeted micelles to restore neuronal proteostasis in Alzheimer's disease","volume":"11","author":"Xu","year":"2022","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0185","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1159\/000238524","article-title":"Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice","volume":"33","author":"Polak","year":"1987","journal-title":"Chemotherapy"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.119844","article-title":"Neuronal mitochondria-targeted micelles relieving oxidative stress for delayed progression of Alzheimer's disease","volume":"238","author":"Yang","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0195","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.neurobiolaging.2005.02.008","article-title":"Cognitive impact of neuronal pathology in the entorhinal cortex and CA1 field in Alzheimer\u2019s disease","volume":"27","author":"von Gunten","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0200","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202004025","article-title":"Rethinking CRITID procedure of brain targeting drug delivery: circulation, blood brain barrier recognition, intracellular transport, diseased cell targeting, internalization, and drug release","volume":"8","author":"Ruan","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0205","doi-asserted-by":"crossref","first-page":"8339","DOI":"10.1002\/anie.201202001","article-title":"Peptide-mediated blood-brain barrier transport of polymersomes","volume":"51","author":"Georgieva","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0210","doi-asserted-by":"crossref","first-page":"9632","DOI":"10.1016\/j.biomaterials.2013.08.045","article-title":"Optimization of Tet1 ligand density in HPMA-co-oligolysine copolymers for targeted neuronal gene delivery","volume":"34","author":"Chu","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0215","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0896-6273(03)00434-3","article-title":"Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction","volume":"39","author":"Oddo","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0220","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neurobiolaging.2005.01.004","article-title":"Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer\u2019s disease: review and hypothesis","volume":"27","author":"Qiu","year":"2006","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0225","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1038\/s41467-020-15120-3","article-title":"Amyloid-\u03b242\/40 ratio drives tau pathology in 3D human neural cell culture models of Alzheimer\u2019s disease","volume":"11","author":"Kwak","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0230","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1523\/JNEUROSCI.20-11-04050.2000","article-title":"High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation","volume":"20","author":"Mucke","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0235","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1097\/00001756-200107200-00009","article-title":"Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies","volume":"12","author":"Kuusisto","year":"2001","journal-title":"Neuroreport"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0240","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0002-9440(10)64369-6","article-title":"p62 is a common component of cytoplasmic inclusions in protein aggregation diseases","volume":"160","author":"Zatloukal","year":"2002","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0245","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1038\/nn.3178","article-title":"Alzheimer amyloid-\u03b2 oligomer bound to postsynaptic prion protein activates Fyn to impair neurons","volume":"15","author":"Um","year":"2012","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0250","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2017.06.004","article-title":"Targeting Fyn kinase in Alzheimer\u2019s disease","volume":"83","author":"Nygaard","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0255","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1750-1326-9-48","article-title":"Oligomeric A\u03b2-induced synaptic dysfunction in Alzheimer\u2019s disease","volume":"9","author":"Tu","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuron.2018.10.014","article-title":"Changes in the synaptic proteome in Tauopathy and Rescue of tau-Induced Synapse Loss by C1q antibodies","volume":"100","author":"Dejanovic","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0265","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/hipo.22607","article-title":"Down-regulation of glutamatergic terminals (VGLUT1) driven by A\u03b2 in Alzheimer's disease","volume":"26","author":"Rodriguez-Perdigon","year":"2016","journal-title":"Hippocampus"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0270","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0275","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1523\/JNEUROSCI.21-04-01179.2001","article-title":"beta-amyloid stimulation of microglia and monocytes results in TNFalpha-dependent expression of inducible nitric oxide synthase and neuronal apoptosis","volume":"21","author":"Combs","year":"2001","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0280","article-title":"Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer\u2019s disease","volume":"2010","author":"Krause","year":"2010","journal-title":"Int. J. Alzheimers Dis."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0285","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1083\/jcb.201709069","article-title":"Microglia in Alzheimer\u2019s disease","volume":"217","author":"Hansen","year":"2017","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0290","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","article-title":"Advanced targeted therapies in cancer: drug nanocarriers, the future of chemotherapy","volume":"93","author":"P\u00e9rez-Herrero","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0295","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.2147\/DDDT.S219489","article-title":"Smart targeting to improve cancer therapeutics","volume":"13","author":"Morales-Cruz","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0300","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/10717544.2018.1428243","article-title":"Therapeutic strategies and nano-drug delivery applications in management of ageing Alzheimer's disease","volume":"25","author":"Karthivashan","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0305","doi-asserted-by":"crossref","DOI":"10.1126\/science.aav9518","article-title":"Amyloid \u03b2 oligomers constrict human capillaries in Alzheimer's disease via signaling to pericytes","volume":"365","author":"Nortley","year":"2019","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0310","doi-asserted-by":"crossref","first-page":"4943","DOI":"10.1016\/j.biomaterials.2011.03.031","article-title":"Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides","volume":"32","author":"Li","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0315","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.actbio.2016.11.029","article-title":"A hybrid siRNA delivery complex for enhanced brain penetration and precise amyloid plaque targeting in Alzheimer\u2019s disease mice","volume":"49","author":"Zheng","year":"2017","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0320","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.nbd.2005.01.022","article-title":"A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting","volume":"19","author":"Liu","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0325","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0330","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0335","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/978-1-61779-080-5_34","article-title":"Analysis of drug interactions","volume":"731","author":"Bijnsdorp","year":"2011","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0340","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.lungcan.2013.08.022","article-title":"Combination of arsenic trioxide and chemotherapy in small cell lung cancer","volume":"82","author":"Zheng","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jconrel.2023.01.074_bb0345","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1158\/1078-0432.CCR-10-2544","article-title":"Combination of farnesyltransferase and Akt inhibitors is synergistic in breast cancer cells and causes significant breast tumor regression in ErbB2 transgenic mice","volume":"17","author":"Balasis","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.jconrel.2023.01.074_bb0350","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1080\/10428190802353591","article-title":"Preclinical versus clinical drug combination studies","volume":"49","author":"Chou","year":"2008","journal-title":"Leuk. Lymphoma"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:45:42Z","timestamp":1759164342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":70,"alternative-id":["S0168365923000834"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.074","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Brain-neuron targeted nanoparticles for peptide synergy therapy at dual-target of Alzheimer's disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.01.074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}